HANGZHOU, China, Feb. 7, 2024 /PRNewswire/ — Cloud Music Inc. (HKEX: 9899 or the “Company”), a well-known online music platform featuring a vibrant content community, today announced that it will report its financial results for the fiscal year of 2023 ended December 31, 2023 on Thursday, February 29, 2024, after the Hong Kong market closes.… Continue reading Cloud Music Inc. to Report Fiscal Year 2023 Financial Results on February 29, 2024
Category: Newswire
Multispectral Camera Market to Reach $4.7 Billion, Globally, by 2032 at 9.41% CAGR: Allied Market Research
The growth of the global multispectral camera is driven by factors such as enhanced border security, counter terrorism and insurgency, maritime security, and domestic production capabilities. WILMINGTON, Del., Feb. 7, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Multispectral Camera Market by Cooling Technology (Cooled and Uncooled), End Use (Man-portable and Payloads), Imaging… Continue reading Multispectral Camera Market to Reach $4.7 Billion, Globally, by 2032 at 9.41% CAGR: Allied Market Research
Innovent’s First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
ROCKVILLE, Md. and SUZHOU, China, Feb. 7, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for mazdutide (Innovent R&D code: IBI362), a… Continue reading Innovent’s First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Youdao to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29
HANGZHOU, China, Feb. 7, 2024 /PRNewswire/ — Youdao, Inc. (“Youdao” or the “Company”) (NYSE: DAO), an intelligent learning company with industry-leading technology in China, today announced that it will report its fourth quarter and fiscal year 2023 financial results on Thursday, February 29, 2024, before the open of the U.S. markets. The earnings teleconference call… Continue reading Youdao to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29
NetEase to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29
HANGZHOU, China, Feb. 7, 2024 /PRNewswire/ — NetEase, Inc. (NASDAQ: NTES and HKEX: 9999, “NetEase” or the “Company”), a leading internet and game services provider, today announced that it will report financial results for the fourth quarter and fiscal year 2023 on Thursday, February 29, 2024, before the open of the U.S. markets. The earnings teleconference… Continue reading NetEase to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29
Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
BLADE-VG2 trial will evaluate the safety and efficacy of STIMULAN VG to treat diabetic foot osteomyelitis BLADE-OPU2 will evaluate the safety and efficacy of STIMULAN VG to treat stage IV pressure ulcers KEELE, England, Feb. 7, 2024 /PRNewswire/ — Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management… Continue reading Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
First patients treated with H-Guard® at the National Institute for Health and Care Research Manchester Clinical Research Facility MHRA approves continuation of Invizius’s first-in-human clinical study following a prearranged two-patient safety and performance review Study is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysis… Continue reading Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
Sports Coaching Market 2023-2028, USD 4.18 billion Incremental Growth – Technavio
NEW YORK, Feb. 7, 2024 /PRNewswire/ — The sports coaching market is set to grow by USD 4.18 billion from 2023 to 2028 progressing at a CAGR of 5.75% during the forecast period. Technavio estimates state that there will be a growth of 5.15% YOY during 2024. The report offers an up-to-date analysis regarding the current global market scenario,… Continue reading Sports Coaching Market 2023-2028, USD 4.18 billion Incremental Growth – Technavio
SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies
STOCKHOLM, Feb. 7, 2024 /PRNewswire/ — SmartCella, through its business unit ProCella, has been approved by the Swedish Medicinal Product Agency for manufacturing and quality control testing of sterile biological medicinal products for cell therapy. SmartCella is pleased to announce that ProCella has been granted manufacturing authorization as well as Good Manufacturing Practice (GMP) certification… Continue reading SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies
Acer Reports January Consolidated Revenues at NT$15.23 Billion, Up 11.7% Year-on-year (YoY), Achieves 7 Months of Consecutive YoY Growth
TAIPEI, Feb. 7, 2024 /PRNewswire/ — Acer Inc. (TWSE: 2353) announced its January 2024 consolidated revenues at NT$15.23 billion with 11.7% growth year-on-year (YoY), achieving seven months of consecutive YoY growth. Some business highlights for January: Chromebooks business revenues grew 39.3% YoY Desktop business revenues grew 16.8% YoY Altos Computing Inc. revenues grew 85.7% YoY… Continue reading Acer Reports January Consolidated Revenues at NT$15.23 Billion, Up 11.7% Year-on-year (YoY), Achieves 7 Months of Consecutive YoY Growth